Cel Sci Corporation (CVM)

[BRMachine]

True, the difference is that companies cannot market the drug for off-label use. In the short term, once approved, doctors and patients can use it for other off-labels cancers, however; the question that remains is whether or not insurance companies will cover MK for off-label use. It may take some time, but you are correct, I believe the market for MK is much much bigger than just head and neck cancer.